We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$124M
1-Year Est. Return
249.88%
This Fund
S&P 500
This Quarter
Est. Return
+50.35%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$164M
AUM Growth
+$44M
(+37%)
Cap. Flow
+$36.1M
Cap. Flow
% of AUM
21.98%
Top 10 Holdings %
Top 10 Hldgs %
70.97%
Holding
38
New
14
Increased
3
Reduced
6
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$12.2M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$9.53M |
| 3 |
AtaiBeckley Inc
ATAI
|
+$9.29M |
| 4 |
SLNO
Soleno Therapeutics
SLNO
|
+$9.17M |
| 5 |
Taysha Gene Therapies
TSHA
|
+$5.37M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VRNA
Verona Pharma
VRNA
|
+$15.2M |
| 2 |
MRUS
Merus
MRUS
|
+$7.37M |
| 3 |
LENZ
LENZ Therapeutics
LENZ
|
+$6.18M |
| 4 |
Enliven Therapeutics
ELVN
|
+$5.64M |
| 5 |
Oric Pharmaceuticals
ORIC
|
+$4.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 72.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLNO
1
DELISTED
Soleno Therapeutics
SLNO
| $20.4M | 12.45% |
302,483
+123,664
| +69% | +$9.17M |
|
|
SLNO
2
CALL
DELISTED
Soleno Therapeutics
SLNO
| $16.9M | 10.29% |
+250,000
| New | +$18.5M |
|
3
CALL
Replimune Group
REPL
$859M
| $15.1M | 9.19% |
+3,600,000
| New | +$23M |
|
|
4
Madrigal Pharmaceuticals
MDGL
$12.8B
| $15M | 9.12% |
+32,662
| New | +$12.2M |
|
|
5
AtaiBeckley Inc
ATAI
$2.67B
| $12.1M | 7.37% |
+2,287,005
| New | +$9.29M |
|
|
6
Ascendis Pharma A/S
ASND
$17.1B
| $10.2M | 6.18% |
+51,080
| New | +$9.53M |
|
|
LENZ
7
LENZ Therapeutics
LENZ
$162M
| $8.17M | 4.97% |
175,363
-167,959
| -49% | -$6.18M |
|
|
CMPS
8
CALL
Compass Pathways
CMPS
$1.67B
| $6.56M | 4% |
+1,145,700
| New | +$5.15M |
|
|
9
Taysha Gene Therapies
TSHA
$1.71B
| $6.21M | 3.78% |
+1,898,112
| New | +$5.37M |
|
10
Amylyx Pharmaceuticals
AMLX
$1.97B
| $5.94M | 3.62% |
+437,391
| New | +$4.12M |
|
|
CMPS
11
Compass Pathways
CMPS
$1.67B
| $5.88M | 3.58% |
1,026,382
-458,618
| -31% | -$2.06M |
|
|
EPRX
12
Eupraxia Pharmaceuticals
EPRX
$431M
| $5.4M | 3.29% |
+915,000
| New | +$4.98M |
|
13
CALL
Praxis Precision Medicines
PRAX
$8.77B
| $5.3M | 3.23% |
+100,000
| New | +$4.85M |
|
14
Monopar Therapeutics
MNPR
$744M
| $5.26M | 3.21% |
64,455
+29,918
| +87% | +$1.34M |
|
15
Arcutis Biotherapeutics
ARQT
$3.56B
| $4.4M | 2.68% |
+233,220
| New | +$3.68M |
|
|
DFTX
16
Definium Therapeutics
DFTX
$5.88B
| $4.26M | 2.6% |
361,444
-364,728
| -50% | -$3.4M |
|
17
Tarsus Pharmaceuticals
TARS
$2.61B
| $4.21M | 2.56% |
70,778
-50,404
| -42% | -$2.48M |
|
18
Solid Biosciences
SLDB
$858M
| $3.39M | 2.06% |
549,182
-174,818
| -24% | -$1.02M |
|
19
ProMIS Neurosciences
PMN
$136M
| $2.65M | 1.61% |
249,340
+195,963
| +367% | +$2.71M |
|
20
Avalo Therapeutics
AVTX
$1.02B
| $2.26M | 1.38% |
+178,100
| New | +$1.53M |
|
|
TECX
21
Tectonic Therapeutic
TECX
$615M
| $2.17M | 1.32% |
138,595
-25,088
| -15% | -$518K |
|
|
WHWK
22
Whitehawk Therapeutics
WHWK
$192M
| $1.55M | 0.95% |
817,939
| – | – |
|
23
CALL
MoonLake Immunotherapeutics
MLTX
$1.64B
| $495K | 0.3% |
+69,000
| New | +$3.6M |
|
|
ATYR
24
CALL
aTyr Pharma
ATYR
$50M
| $433K | 0.26% |
+600,000
| New | +$2.72M |
|
|
CNTA
25
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-293,986
| Closed | -$3.86M |
|
Similar funds
MP
EWP
WFA
VWM
EI
TC
IFO
CRW
Ally Bridge Group's Q3 2025 Portfolio in Review
As of Q3 2025, Ally Bridge Group held 38 positions worth $164M, up 37% from $120M the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Ally Bridge Group deployed $36.1M of net new capital in Q3 2025, opening 14 new positions and adding to 3 existing holdings. Its largest new stake was Madrigal Pharmaceuticals: 32,662 shares worth $15M.
By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 95% a quarter earlier.
On the sell side, the largest reduction was LENZ Therapeutics, an estimated $6.18M trimmed.
- Ally Bridge Group's largest Q3 2025 buy was Madrigal Pharmaceuticals: 32,662 shares worth $15M.
- Ally Bridge Group added most to Soleno Therapeutics in Q3 2025, an estimated $9.17M increase.
- Ally Bridge Group's biggest Q3 2025 reduction was LENZ Therapeutics, cutting an estimated $6.18M.
- Ally Bridge Group fully exited Verona Pharma in Q3 2025, selling an estimated $15.2M.
- Ally Bridge Group's ten largest holdings make up 71% of its $164M portfolio in Q3 2025.
- Ally Bridge Group opened 14 new positions and closed 14 in Q3 2025.
- Ally Bridge Group's portfolio value rose 37% quarter-over-quarter to $164M.
Based on Ally Bridge Group's 13F filing for Q3 2025, filed 14 Nov 2025.